Logos Global Management LP
San Francisco, CA · CIK 1792126 · 13F filing filed 2022-08-15
SEC-registered investment adviser since 2019 · limited partnership
- Assets managed$2.3bn
- Staff9 · 5 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds5 (1 hedge) · $2.3bn gross assets
- Form ADV · 2026-04-22SEC adviser record
- Legal entityLOGOS GLOBAL MANAGEMENT LP (US)
- Kindhedge funds, venture, futures
- Others nearbySan Francisco, CA
As an employer
- Offices in1 country
- Private fundshedge 1, venture capital 4
US visa salary filings
- Filings FY20252
- Median salary offered$160,000
- Middle half$160,000 – $160,000
- Job titles1
| Job title | Filings | Median |
|---|---|---|
| Senior AnalystLong Island City, NY | 2 | $160,000 |
Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: Logos Global Management LP.
Holdings, Q2 2022
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| CYTOKINETICS INC CYTK | $68.8m12.61% | Added +135.0k |
| APELLIS PHARMACEUTICALS INC APLS | $67.8m12.44% | Added +600.0k |
| IDEAYA BIOSCIENCES INC IDYA | $51.8m9.49% | Added +900.0k |
| DESIGN THERAPEUTICS INC DSGN | $39.2m7.19% | Unchanged |
| SAREPTA THERAPEUTICS INC SRPT | $30.0m5.50% | New |
| NEUROCRINE BIOSCIENCES INC NBIX | $29.2m5.37% | Reduced -175.0k |
| BICYCLE THERAPEUTICS PLC BCYC | $28.5m5.23% | Added +750.0k |
| VENTYX BIOSCIENCES INC VTYX | $28.3m5.19% | Reduced -201.6k |
| HORIZON THERAPEUTICS PUB L HZNP | $27.9m5.12% | New |
| ALX ONCOLOGY HLDGS INC ALXO | $25.4m4.65% | Added +125.0k |
| ARCUTIS BIOTHERAPEUTICS INC ARQT | $21.3m3.91% | Reduced -500.0k |
| DYNE THERAPEUTICS INC DYN | $19.9m3.66% | Added +165.6k |
| KARUNA THERAPEUTICS INC COM | $19.0m3.48% | Reduced -190.0k |
| DICE THERAPEUTICS INC COM | $15.3m2.81% | Reduced -400.0k |
| OLEMA PHARMACEUTICALS INC OLMA | $15.2m2.80% | Unchanged |
| CHEMOCENTRYX INC CCXI | $14.9m2.73% | New |
| FULCRUM THERAPEUTICS INC FULC | $9.6m1.75% | Added +950.0k |
| ACADIA PHARMACEUTICALS INC ACAD | $9.2m1.68% | New |
| KEZAR LIFE SCIENCES INC COM | $7.9m1.44% | Reduced -664.0k |
| CENTURY THERAPEUTICS INC IPSC | $4.0m0.73% | Reduced -73.7k |
| CENTESSA PHARMACEUTICALS PLC SPONSORED ADS | $1.9m0.36% | Reduced -54.7k |
| SPRUCE BIOSCIENCES INC COM | $1.7m0.32% | Unchanged |
| INSTIL BIO INC COM | $1.7m0.31% | Reduced -7.3k |
| TALARIS THERAPEUTICS INC COM | $1.2m0.22% | Reduced -35.2k |
| EDGEWISE THERAPEUTICS INC EWTX | $1.2m0.22% | Reduced -63.7k |
| TYRA BIOSCIENCES INC TYRA | $1.2m0.22% | Reduced -86.2k |
| LIANBIO LIANY | $852.0k0.16% | Reduced -18.4k |
| ATHIRA PHARMA INC COM | $671.0k0.12% | Reduced -497.3k |
| VIGIL NEUROSCIENCE INC VIGL | $530.0k0.10% | Unchanged |
| PYXIS ONCOLOGY INC PYXS | $525.0k0.10% | Reduced -66.2k |
| NUVALENT INC COM | $460.0k0.08% | Reduced -100.8k |
| NUVATION BIO INC NUVB.WS | $19.0k0.00% | Unchanged |
Sold out since Q1 2022
| Security | Value then |
|---|---|
| GLOBAL BLOOD THERAPEUTICS IN GBT | $43.3m1.2m shares |
| IVERIC BIO INC OPHT | $30.3m1.8m shares |
| MIRATI THERAPEUTICS INC MRTX | $28.8m350.0k shares |
| ASCENDIS PHARMA A/S | $20.5m175.0k shares |
| IOVANCE BIOTHERAPEUTICS INC IOVA | $16.6m1.0m shares |
| JOUNCE THERAPEUTICS INC JNCE | $9.5m1.4m shares |
| VERA THERAPEUTICS INC VERA | $9.0m385.0k shares |
| SCHOLAR ROCK HLDG CORP SRRK | $8.7m675.0k shares |
| ANAPTYSBIO INC ANAB | $7.4m300.0k shares |
| VERVE THERAPEUTICS INC | $2.2m96.9k shares |
| CULLINAN THERAPEUTICS INC CGEM | $2.1m200.0k shares |
| VERONA PHARMA PLC VRNA | $1.5m300.0k shares |
| VISTAGEN THERAPEUTICS INC VTGN | $1.2m1.0m shares |
| COGENT BIOSCIENCES INC COGT | $1.1m150.0k shares |
| IKENA ONCOLOGY INC | $1.1m178.3k shares |
| BIOMEA FUSION INC BMEA | $892.0k200.0k shares |
| SOMALOGIC INC SLGC | $802.0k100.0k shares |
| RAIN ONCOLOGY INC | $680.0k134.2k shares |
| OMEGA THERAPEUTICS INC | $81.0k13.0k shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| ACHIEVE LIFE SCIENCES INC ACHV · 13G · filed 2026-08-17 | 10.0%≈ $68.8m |
| PALATIN TECHNOLOGIES INC PTN · 13G · filed 2026-05-15 | 9.9%≈ $2.0m |
| MINERVA NEUROSCIENCES INC NERV · 13G · filed 2026-02-17 | 9.9%≈ $24.6m |